Should I Buy BRTX? BRTX 2026 Analysis

Should You Buy BioRestorative Therapies Inc (BRTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.250

1 Day change

-2.34%

52 Week Range

2.050

Analysis Updated At

2026/04/03

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BioRestorative Therapies Inc (BRTX) is not a strong buy at this time for a beginner investor with a long-term focus. The stock lacks positive trading signals, has weak financial performance, and shows no significant positive catalysts or recent news to support a bullish case. While the analyst maintains a Buy rating, the price target is significantly higher than the current price, but the lack of clear momentum or strong fundamentals makes this a hold for now.

Technical Analysis

The MACD is above 0 but positively contracting, RSI is neutral at 47.618, and moving averages are converging, indicating no strong trend. The stock is trading below the pivot level of 0.291, with support at 0.261 and resistance at 0.321. Overall, technical indicators suggest a lack of clear direction.

Positive Catalysts

Analyst Jonathan Aschoff from Roth Capital maintains a Buy rating with a reduced price target of $15, citing encouraging trends in Phase 2 trial data for BRTX-100.

Neutral/Negative Catalysts

The company reported a significant YoY revenue decline of -54.73% in Q4 2025, and gross margin slightly dropped. The lack of recent news, neutral insider and hedge fund sentiment, and no recent congress trading data further weaken the case for immediate investment.

Financial Performance

In Q4 2025, revenue dropped significantly by -54.73% YoY to $19,600. Net income improved to -$3,207,636 (up 96.05% YoY), and EPS increased to -0.33 (up 65% YoY). However, the financials still reflect a struggling company with weak revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital analyst maintains a Buy rating but lowered the price target from $18 to $15 due to errors in interim Phase 2 trial data reporting. The analyst remains optimistic about the trial's success if current trends continue.

1 Analyst Rating

Wall Street analysts forecast BRTX stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.257

Low

Averages

High

Current: 0.257

Low

Averages

High

Roth Capital

Jonathan Aschoff

Buy

downgrade

$18 -> $15

AI Analysis

2026-04-02

Reason

Roth Capital

Jonathan Aschoff

Price Target

$18 -> $15

AI Analysis

2026-04-02

downgrade

Buy

Reason

Roth Capital analyst Jonathan Aschoff lowered the firm's price target on BioRestorative Therapies to $15 from $18 and keeps a Buy rating on the shares. In the company's updated interim blinded results from its Phase 2 trial evaluating BRTX-100 in cLDD patients, the press release contained the "wrong" patient numbers for over-50% improvement, though the percent of patients that achieved the thresholds at the timepoints was still accurate, the analyst tells investors in a research note. Despite the large caveat that comes with drawing conclusions from blinded data, the most recent data continue the encouraging trend, and as long as the data trend continues, and response ends up falling along randomization lines as is currently assumed, it appears as if the trial will succeed, Roth added.

BRTX Should I Buy

BRTX Should I Buy

Should You Buy BioRestorative Therapies Inc (BRTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch